Literature DB >> 1570389

Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight and the behavioural satiety sequence.

J McGuirk1, R Muscat, P Willner.   

Abstract

Rats were administered fenfluramine (FF: 3 mg/kg) or fluoxetine (FX: 6 mg/kg) daily for 3 weeks. On acute administration, FF suppressed consumption of 35% sucrose (in a 40 min test) and overnight chow intake. Repeated administration saw the rapid development of extensive tolerance to these effects. FF had no effects on body weight, and no withdrawal effects were apparent. FX reduced chow intake and body weight throughout the treatment period, but there was evidence of some tolerance to the suppression of chow intake and sucrose drinking. Following FX withdrawal, normal body weight was restored in 4 days; food intake was normal during this period. A delayed rebound hyperphagia commenced on day 5 of withdrawal, and persisted for at least 6 days. The behavioural satiety sequence (drinking--activity--grooming--resting) was disrupted by acute FF; on chronic treatment, FF advanced the onset of postprandial resting, but also increased drinking time. FX advanced the behavioural satiety sequence on acute administration, but not after chronic treatment. We consider the implications of these results for the use of resting behaviour as an indicator of postprandial satiety.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1570389     DOI: 10.1007/bf02245426

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release.

Authors:  R W Fuller; H D Snoddy; D W Robertson
Journal:  Pharmacol Biochem Behav       Date:  1988-07       Impact factor: 3.533

2.  Food intake in baboons: effects of d-amphetamine and fenfluramine.

Authors:  R W Foltin; M W Fischman
Journal:  Pharmacol Biochem Behav       Date:  1988-11       Impact factor: 3.533

Review 3.  Serotonin manipulations and the structure of feeding behaviour.

Authors:  J E Blundell
Journal:  Appetite       Date:  1986       Impact factor: 3.868

4.  An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice.

Authors:  J E Morley; J F Flood
Journal:  Life Sci       Date:  1987-11-02       Impact factor: 5.037

5.  Feeding parameters with two food textures after chlordiazepoxide administration, alone or in combination with d-amphetamine or fenfluramine.

Authors:  S J Cooper; R L Francis
Journal:  Psychopharmacology (Berl)       Date:  1979-04-25       Impact factor: 4.530

6.  Behavioural analysis of the anorectic effects of fluoxetine and fenfluramine.

Authors:  P Willner; J McGuirk; G Phillips; R Muscat
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Fluoxetine suppresses palatability-induced ingestion.

Authors:  J D Leander
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity.

Authors:  L R Levine; S Rosenblatt; J Bosomworth
Journal:  Int J Obes       Date:  1987

9.  Behavioral correlates of oral and postingestive satiety in the rat.

Authors:  L R Kushner; D G Mook
Journal:  Physiol Behav       Date:  1984-11

10.  The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects.

Authors:  J McGuirk; T Silverstone
Journal:  Int J Obes       Date:  1990-04
View more
  10 in total

1.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 2.  How the cerebral serotonin homeostasis predicts environmental changes: a model to explain seasonal changes of brain 5-HTT as intermediate phenotype of the 5-HTTLPR.

Authors:  Jan Kalbitzer; Urs Kalbitzer; Gitte Moos Knudsen; Paul Cumming; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2013-10-23       Impact factor: 4.530

Review 3.  Collateralized dorsal raphe nucleus projections: a mechanism for the integration of diverse functions during stress.

Authors:  Maria Waselus; Rita J Valentino; Elisabeth J Van Bockstaele
Journal:  J Chem Neuroanat       Date:  2011-05-30       Impact factor: 3.052

4.  Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats.

Authors:  S P Vickers; K R Benwell; R H Porter; M J Bickerdike; G A Kennett; C T Dourish
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

5.  Further studies to examine the nature of dexfenfluramine-induced suppression of heroin self-administration.

Authors:  Y Wang; N Joharchi; P J Fletcher; E M Sellers; G A Higgins
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

6.  Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype.

Authors:  S P Vickers; P G Clifton; C T Dourish
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

7.  Fluoxetine induces lean phenotype in rat by increasing the brown/white adipose tissue ratio and UCP1 expression.

Authors:  A I da Silva; G R F Braz; A A Pedroza; L Nascimento; C M Freitas; D J S Ferreira; R Manhães de Castro; C J Lagranha
Journal:  J Bioenerg Biomembr       Date:  2015-07-01       Impact factor: 2.945

Review 8.  The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics.

Authors:  Rebecca G Boswell; Marc N Potenza; Carlos M Grilo
Journal:  Clin Ther       Date:  2020-11-27       Impact factor: 3.393

Review 9.  The use of serotonergic drugs to treat obesity--is there any hope?

Authors:  Nicholas T Bello; Nu-Chu Liang
Journal:  Drug Des Devel Ther       Date:  2011-02-10       Impact factor: 4.162

10.  Updates on Antiobesity Effect of Garcinia Origin (-)-HCA.

Authors:  Li Oon Chuah; Wan Yong Ho; Boon Kee Beh; Swee Keong Yeap
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-06       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.